Comparative Pharmacology
Head-to-head clinical analysis: DYCLOPRO versus LODINE XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCLOPRO versus LODINE XL.
DYCLOPRO vs LODINE XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diclofenac epolamine inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and consequent inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
50 mg intravenously every 8 hours
400 mg or 600 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in adults with normal renal function; may be prolonged in renal impairment (up to 8-12 hours).
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Primarily renal (approximately 70% as unchanged drug and metabolites); biliary/fecal excretion accounts for about 30%.
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Category C
Category C
NSAID
NSAID